FibroBiologics Completes First Batch Manufacturing of CYWC628 Drug
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 31 2026
0mins
Should l Buy FBLG?
FibroBiologics announced the completion of manufacturing of the first batch of FibroBiologics' proprietary CYWC628 drug product that will support upcoming first-in-human clinical trials. Manufactured in accordance with the FDA's Good Manufacturing Practices, the drug product will be released after it successfully passes all required safety and quality testing. "CYWC628 is not only the first fibroblast-based spheroid therapeutic candidate, its manufacture also represents the first large-scale CGMP manufacturing of a spheroid product for therapeutic use," said Pete O'Heeron, Founder and CEO of FibroBiologics. "These achievements by our scientific team allow us to move forward with our planned Phase 1/2 clinical trial utilizing CYWC628 in DFU patients in the first half of 2026."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FBLG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FBLG
Wall Street analysts forecast FBLG stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.380
Low
1.50
Averages
3.25
High
5.00
Current: 1.380
Low
1.50
Averages
3.25
High
5.00
About FBLG
FibroBiologics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). It is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. It is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FibroBiologics Unveils Data on Reversing Immune Decline
- Immune Function Restoration: FibroBiologics' research indicates that its proprietary thymic organoid platform can reverse age-related immune decline by restoring thymic function, enhancing T cell production capacity, thereby improving the body's resistance to infections and cancer.
- Diverse T Cell Generation: In immunodeficient mouse models, transplanted thymic organoids successfully generated multiple T cell lineages, including αβ T cells and γδ T cells, demonstrating their biological activity and diversity in vivo, indicating potential for clinical applications.
- Anti-Tumor Activity: T cells derived from thymic organoids exhibited anti-tumor activity in a targeted cancer model against melanoma, slowing tumor growth and enhancing natural killer cell activation, suggesting a systemic immune response rather than localized effects.
- Clinical Application Prospects: The findings from FibroBiologics not only provide a new solution for age-related immune decline but also hold significant potential in recovery following chemotherapy or radiation, as well as in congenital disorders caused by loss of thymic function.
See More
FibroBiologics Achieves Key Milestone with CYWC628 Drug Batch Manufacturing
- Drug Production Milestone: FibroBiologics successfully manufactured its first batch of CYWC628, marking a significant advancement in its diabetic foot ulcer program, with plans to initiate clinical trials in DFU patients in the first half of 2026.
- Compliance with Standards: The batch was produced under FDA-compliant Good Manufacturing Practices, ensuring product safety and quality, which demonstrates the company's expertise in biopharmaceuticals and commitment to patient safety.
- Funding Initiative: FibroBiologics concurrently announced a public offering of 2,272,728 shares at $1.32 each, aiming to raise approximately $3 million, with proceeds designated for operational and clinical development, thereby enhancing the company's financial stability.
- Stock Price Volatility: Despite the production progress, FBLG's stock has experienced significant fluctuations, closing at $1.31 yesterday, down 42.11% from the previous day, indicating market caution regarding the company's outlook.
See More
FibroBiologics Prices Public Offering at $1.32 per Share
- Offering Details: FibroBiologics announced a public offering of 2,272,728 shares at $1.32 each, with expected gross proceeds of approximately $3 million, reflecting the company's proactive fundraising strategy in the capital markets.
- Warrant Terms: The warrants will also have an exercise price of $1.32 per share and will be exercisable upon stockholder approval, valid for five years, providing potential liquidity support for the company's future operations.
- Use of Proceeds: The net proceeds from this offering will be allocated for working capital and general corporate purposes, indicating the company's commitment to advancing its biotechnology research and market expansion efforts.
- Regulatory Compliance: The offering is conducted under an SEC registration statement, ensuring compliance and transparency, which further enhances investor confidence in the company's future growth prospects.
See More
FibroBiologics Prices Public Offering at $1.32 per Share
- Offering Size: FibroBiologics announced a public offering of 2,272,728 shares at $1.32 each, with expected gross proceeds of approximately $3 million, demonstrating the company's proactive capital raising capabilities in the market.
- Warrant Details: The warrants will also have an exercise price of $1.32 and will become exercisable upon stockholder approval, remaining valid for five years, which provides potential future funding security for the company.
- Use of Proceeds: The net proceeds from this offering will be allocated for working capital and general corporate purposes, indicating the company's commitment to advancing its biotechnology research and market expansion efforts.
- Market Reaction: With H.C. Wainwright & Co. acting as the exclusive placement agent, this offering is expected to enhance market visibility for FibroBiologics and could positively influence its stock price.
See More
FibroBiologics Files for $5M Public Offering Amid Reverse Split
- Public Offering Plan: FibroBiologics has filed an amended registration statement for a public offering of approximately 1.14 million units, expected to raise about $5 million in gross proceeds to support the company's operations and development.
- Reverse Split Strategy: This offering is strategically timed with a 1-for-20 reverse stock split effective March 30, 2026, aimed at elevating the company's share price to comply with Nasdaq's $1.00 minimum bid price requirement, thereby enhancing market confidence.
- Unit Composition Details: Each unit consists of one share of common stock (or one pre-funded warrant) and one common warrant priced at $4.40 per unit, with warrants expiring five years after issuance or stockholder approval, increasing potential returns for investors.
- Planned Use of Proceeds: The company intends to utilize the net proceeds (approximately $4.3 million) for working capital and general corporate purposes, including the continued development of its fibroblast-based therapeutic pipeline, demonstrating its commitment to future growth.
See More
FibroBiologics Approves 1-for-20 Reverse Stock Split
- Reverse Split Decision: FibroBiologics' board approved a 1-for-20 reverse stock split to meet Nasdaq Capital Market's minimum bid price requirements, thereby mitigating delisting risks and enhancing market confidence.
- Effective Date: The reverse split will take effect on March 30, with trading on a split-adjusted basis starting the same day, reducing outstanding shares from approximately 70.3 million to about 3.5 million, significantly increasing the per-share value.
- Shareholder Authorization: This reverse split has been previously authorized by shareholders, indicating the company's commitment to maintaining its listing status while potentially attracting more investor interest in its stock.
- Market Reaction Expectations: By implementing the reverse split, FibroBiologics aims to restore compliance and boost investor interest; although it may face market volatility in the short term, it is expected to improve the company's image and shareholder value in the long run.
See More
FibroBiologics Unveils Data on Reversing Immune Decline
- Immune Function Restoration: FibroBiologics' research indicates that its proprietary thymic organoid platform can reverse age-related immune decline by restoring thymic function, enhancing T cell production capacity, thereby improving the body's resistance to infections and cancer.
- Diverse T Cell Generation: In immunodeficient mouse models, transplanted thymic organoids successfully generated multiple T cell lineages, including αβ T cells and γδ T cells, demonstrating their biological activity and diversity in vivo, indicating potential for clinical applications.
- Anti-Tumor Activity: T cells derived from thymic organoids exhibited anti-tumor activity in a targeted cancer model against melanoma, slowing tumor growth and enhancing natural killer cell activation, suggesting a systemic immune response rather than localized effects.
- Clinical Application Prospects: The findings from FibroBiologics not only provide a new solution for age-related immune decline but also hold significant potential in recovery following chemotherapy or radiation, as well as in congenital disorders caused by loss of thymic function.
See More
FibroBiologics Achieves Key Milestone with CYWC628 Drug Batch Manufacturing
- Drug Production Milestone: FibroBiologics successfully manufactured its first batch of CYWC628, marking a significant advancement in its diabetic foot ulcer program, with plans to initiate clinical trials in DFU patients in the first half of 2026.
- Compliance with Standards: The batch was produced under FDA-compliant Good Manufacturing Practices, ensuring product safety and quality, which demonstrates the company's expertise in biopharmaceuticals and commitment to patient safety.
- Funding Initiative: FibroBiologics concurrently announced a public offering of 2,272,728 shares at $1.32 each, aiming to raise approximately $3 million, with proceeds designated for operational and clinical development, thereby enhancing the company's financial stability.
- Stock Price Volatility: Despite the production progress, FBLG's stock has experienced significant fluctuations, closing at $1.31 yesterday, down 42.11% from the previous day, indicating market caution regarding the company's outlook.
See More
FibroBiologics Prices Public Offering at $1.32 per Share
- Offering Details: FibroBiologics announced a public offering of 2,272,728 shares at $1.32 each, with expected gross proceeds of approximately $3 million, reflecting the company's proactive fundraising strategy in the capital markets.
- Warrant Terms: The warrants will also have an exercise price of $1.32 per share and will be exercisable upon stockholder approval, valid for five years, providing potential liquidity support for the company's future operations.
- Use of Proceeds: The net proceeds from this offering will be allocated for working capital and general corporate purposes, indicating the company's commitment to advancing its biotechnology research and market expansion efforts.
- Regulatory Compliance: The offering is conducted under an SEC registration statement, ensuring compliance and transparency, which further enhances investor confidence in the company's future growth prospects.
See More
FibroBiologics Prices Public Offering at $1.32 per Share
- Offering Size: FibroBiologics announced a public offering of 2,272,728 shares at $1.32 each, with expected gross proceeds of approximately $3 million, demonstrating the company's proactive capital raising capabilities in the market.
- Warrant Details: The warrants will also have an exercise price of $1.32 and will become exercisable upon stockholder approval, remaining valid for five years, which provides potential future funding security for the company.
- Use of Proceeds: The net proceeds from this offering will be allocated for working capital and general corporate purposes, indicating the company's commitment to advancing its biotechnology research and market expansion efforts.
- Market Reaction: With H.C. Wainwright & Co. acting as the exclusive placement agent, this offering is expected to enhance market visibility for FibroBiologics and could positively influence its stock price.
See More
FibroBiologics Files for $5M Public Offering Amid Reverse Split
- Public Offering Plan: FibroBiologics has filed an amended registration statement for a public offering of approximately 1.14 million units, expected to raise about $5 million in gross proceeds to support the company's operations and development.
- Reverse Split Strategy: This offering is strategically timed with a 1-for-20 reverse stock split effective March 30, 2026, aimed at elevating the company's share price to comply with Nasdaq's $1.00 minimum bid price requirement, thereby enhancing market confidence.
- Unit Composition Details: Each unit consists of one share of common stock (or one pre-funded warrant) and one common warrant priced at $4.40 per unit, with warrants expiring five years after issuance or stockholder approval, increasing potential returns for investors.
- Planned Use of Proceeds: The company intends to utilize the net proceeds (approximately $4.3 million) for working capital and general corporate purposes, including the continued development of its fibroblast-based therapeutic pipeline, demonstrating its commitment to future growth.
See More
FibroBiologics Approves 1-for-20 Reverse Stock Split
- Reverse Split Decision: FibroBiologics' board approved a 1-for-20 reverse stock split to meet Nasdaq Capital Market's minimum bid price requirements, thereby mitigating delisting risks and enhancing market confidence.
- Effective Date: The reverse split will take effect on March 30, with trading on a split-adjusted basis starting the same day, reducing outstanding shares from approximately 70.3 million to about 3.5 million, significantly increasing the per-share value.
- Shareholder Authorization: This reverse split has been previously authorized by shareholders, indicating the company's commitment to maintaining its listing status while potentially attracting more investor interest in its stock.
- Market Reaction Expectations: By implementing the reverse split, FibroBiologics aims to restore compliance and boost investor interest; although it may face market volatility in the short term, it is expected to improve the company's image and shareholder value in the long run.
See More
